The hepatotoxicity/cytotoxicity assays provide a means to measure cell death due to the cytotoxic effect of a test compound. We provide hepatotoxicity/cytotoxicity assays for all small molecule formulations such as pharmaceuticals, industrial chemicals and consumer products.
Our hepatotoxicity/cytotoxicity assays use a genetically modified version of the metabolically active immortalized human liver cell line HepaRG™, created with our proprietary CompoZr® zinc finger (ZFN) nuclease technology.
Hepatotoxicity is the leading cause of late-stage drug attrition and there is great interest in understanding the potential for a drug to cause liver damage. Primary human hepatocytes are the gold standard for these types of studies, but limited availability, high cost, donor-to-donor variability and other concerns limit their application on a broader scale. Apart from human hepatocytes, HepaRG™ cells are the most metabolically active liver cell line described to date and have the potential for use as a viable surrogate in many functional liver assays, including hepatotoxicity testing.
We offer hepatotoxicity screening with a variety of individual or multiple endpoints. Cytotoxicity is typically assessed using MTT, but other endpoints may be substituted, including neutral red, LDH or ATP depletion. Follow-up assays can be added to determine whether cell death occurs via necrosis or apoptosis.
Hepatotoxicity Assay Protocol